COMPANY PROFILE

Rapport Therapeutics

Developing recision medicines to match the complexity of the human brain

Boston, United StatesFounded 2022Biotech & Life Sciences

Valuation $1.22B Market cap · 2026

Revenue $20M Latest reported FY

About Rapport Therapeutics

Rapport Therapeutics is a scientific partnership startup focused on the development of precision neuromedicines. The company is led by Steve, a seasoned professional with over 40 years of R&D leadership experience. He has co-founded and led multiple companies in the biotechnology and pharmaceutical industry, including Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics.

Rapport operates in the healthcare and pharmaceutical market, specifically targeting neurological disorders. The company's primary clients are patients suffering from drug-resistant epilepsies and mood disorders. Rapport's business model revolves around the discovery and development of novel drugs that act only on disease-relevant areas in the brain, thereby reducing symptoms and side effects of treatment regimens.

Rapport's discovery platform is designed to identify drugs with selectivity to enhance patient benefit. This is achieved by embedding region-specific RAPs (Receptor Associated Proteins) into their drug discovery and development processes. RAPs function in discrete and specific cell types or brain regions, and by targeting these areas, Rapport aims to create more effective treatments for neurological disorders.

The company generates revenue through the development and sale of these precision neuromedicines. Additionally, they may also earn income from conducting clinical trials and providing related services.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2022
Headquarters: Boston, United States
Listing: IPO 2024
Employees: 102
Open positions: 12
Dealroom signal: 57.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Sep 2025	$250M	—	Undisclosed	↗
IPOOther financing	Jun 2024	$154M	$601M	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$20M	—	−$124M	-620.4%
2025	$0	—	−$124M	—
2024	$0	—	−$82M	—
2023	$0	—	−$34M	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Rapport Therapeutics website traffic

Latest recorded traffic for Rapport Therapeutics is 7.8K monthly website visits, up 25.8% over the last three months. Rapport Therapeutics's team grew 15.9% over the past year.

Latest monthly visits7.8K 3-month web change+25.8% 1-year team growth+15.9%

Monthly website visitsMar 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

VP, Business DevelopmentBoston, MA · Business Development · Aug 25, 2026 Sr. Clinical Trial AssociateBoston, MA · Other · Aug 24, 2026 Associate Director/Director, Regulatory StrategyBoston, MA · Other · Aug 23, 2026 Senior Clinical Trial ManagerBoston, MA · Other · Aug 18, 2026 Senior Manager/Associate Director, BiostatisticsGreater Boston · Other · Aug 18, 2026 Associate Director, Medical WritingBoston, MA · Other · Aug 18, 2026 Senior Manager/Associate Director, Statistical ProgrammingBoston, MA · Accounting · Aug 18, 2026 VP, Program LeaderBoston, MA · Other · Aug 15, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational	292	$394M	$1.5B
AAAdvanced Accelerator ApplicationsDevelops diagnostic and therapeutic products in the field of molecular nuclear medicine	Saint-Genis-Pouilly, France	Acquired
SPSupernus PharmaceuticalsSpecialty pharmaceutical firm commercializing central nervous system treatments	Rockville, United States	Operational
DTDianthus TherapeuticsBiotech company developer of therapeutics and drugs	New York City, United States	Operational
NUNurixDevelops small molecule inhibitors for the treatment of proliferative and degenerative diseases	San Francisco, United States	Operational
MIMoonLake ImmunotherapeuticsMoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases	Zug, Switzerland	Operational
NPNewAmsterdam PharmaDeveloping transformative, clinically validated oral therapies for patients with metabolic diseases	Aventura, United States	Operational
TTTaysha Gene TherapiesOn a mission to eradicate monogenic CNS disease	Dallas, United States	Operational